The Investigator's Brochure Has Become a Regulated Safety Instrument. Is Your Organisation Ready?

For the past 30 years, the structure and expected content of the Investigator's Brochure (IB) have remained remarkably static. Since the International Council for Harmonisation (ICH) published the E6(R1) Guideline for Good Clinical Practice in 1996, the IB's fundamental architecture—summary, introduction, physical/chemical properties, non-clinical studies, effects in humans, and guidance for the investigator, has persisted with minimal substantive revision [1]. During this period, the IB has arguably become the single most important regulatory document in clinical development. It serves as the primary reference for investigators assessing benefit-risk, underpins clinical trial authorisations, informs ethics committee reviews, and provides the foundation for safety reporting decisions throughout a product's development lifecycle. It has also served as a sales brochure for many a biotech sale.

The Niche Science & Technology team has been at the forefront of critical commentary on the IB over the last decade, producing the widely-downloaded "Insider's Insight" series and participating in the European Federation for Exploratory Medicines (EUFEMED) initiative, which published recommendations in 2021 to improve the IB's focus for early-phase investigators [2][3]. This work culminated in a landmark multi-stakeholder workshop in Warsaw on 20 September 2024, where key industry professionals, academics, investigators, regulators and ethics committee members convened to develop consensus guidelines for keeping end-users at the centre of IB development [4].

However, as these important initiatives progressed, the clinical research landscape has fundamentally shifted. The biggest issue facing Investigator’s Brochures in 2026 is not formatting inconsistencies, data gaps, or cross-functional bottlenecks. It is the full-scale transition to ICH E6 (R3) [5], and the profound ripple effects this revision is creating across safety reporting, evidence quality, and operational governance. Compounding this global challenge is a critical structural vulnerability that has emerged in Australia, where the IB serves as the primary, and often the sole, source of safety information for those giving permission to conduct clinical trials.

E6 (R3): A Reset, Not an Update

ICH E6 (R3) became effective in the European Union on 23 July 2025 [5], with other major regulatory authorities, including Singapore's Health Sciences Authority, implementing the guideline from 1 January 2026 [6][7]. This revision does not merely update terminology or offer incremental improvements. It fundamentally rewrites the expectations for how an IB is built, maintained, justified, and defended throughout a product's development.

The guideline's new architecture reflects this paradigm shift. E6 (R3) is now organised into core principles supported by annexes and appendices, with the IB addressed specifically in Appendix A [6]. As clinical research professionals have noted, "E6(R3) shifts us from checklists to critical thinking" [8]. For the IB, this translates into three transformative changes: significantly strengthened Reference Safety Information (RSI) requirements, a more prescriptive approach to content and currency, and an explicit expectation that the IB functions as a genuinely ‘living document.’

Where Safety Reporting Depends on Getting It Right

The most critical pressure point in E6 (R3) concerns the Reference Safety Information (RSI). The RSI, defined as the cumulative list of adverse drug reactions (ADRs) expected for an investigational product, directly drives expectedness assessments, SUSAR (Suspected Unexpected Serious Adverse Reaction) reporting decisions, and the sponsor's entire safety signal posture [9].

Under E6 (R3), the RSI must include not only a list of expected serious adverse reactions but also information on their frequency and nature [7]. Each "expected" serious adverse reaction included in the RSI must have a reasonable evidence base establishing causality, typically requiring that such reactions have been observed as suspected SARs multiple times [10]. If the RSI is incomplete, sponsors risk classifying expected events as unexpected. If the RSI is overly inclusive, the Sponsor risks failing to identify genuine safety signals. If the RSI is inaccurate in frequency estimation, every downstream expedited reporting decision becomes compromised.

The consequences of an inaccurate RSI cascade through the entire safety system. An incorrect expectedness determination leads to either unnecessary expedited reporting (wasting regulatory and sponsor resources) or, more concerningly, failure to report genuine SUSARs in a timely manner. Given that the IB remains the reference document for determining whether an adverse event is related to investigational product administration, the margin for error is thin and the potential for patient harm significant.

The Living Document Mandate

E6 (R3) also transforms expectations for IB currency. While the previous guideline recommended annual review, the revision states that the IB “should be reviewed at least annually and revised as necessary in compliance with a sponsor’s documented procedures” while explicitly noting that “more frequent revision may be appropriate depending on the stage of development and the generation of relevant new information” [5][9].

Perhaps most significantly, the guideline acknowledges that “relevant new information may be so important that it needs to be communicated to the investigators and possibly to the institutional review boards/independent ethics committees and/or regulatory authorities before it is included in a revised IB” [5][9]. This creates, for the first time, an explicit regulatory pathway for out-of-cycle IB updates driven by emerging safety data.

Furthermore, the section on effects in humans must now provide a summary of ongoing trials where interim results may inform safety evaluation [7]. This requires IB authors and sponsors to maintain real-time awareness of evolving data streams and exercise professional judgement about what constitutes information that may inform safety evaluation from blinded or incomplete trial data.

The Australian Anomaly: When the IB Stands Alone

While the global shift to E6 (R3) presents universal challenges, a uniquely concerning situation has emerged in Australia that appears to compound the risks inherent in the new framework. Unlike most major regulatory jurisdictions, where the IB is typically reviewed alongside an Investigational New Drug (IND) application in the United States or an Investigational Medicinal Product Dossier (IMPD) in Europe, Australian regulators at the Therapeutic Goods Administration (TGA) and Human Research Ethics Committees (HRECs) rely almost exclusively on the IB as their primary source of safety and technical information [11].

The Clinical Trial Notification (CTN) and Clinical Trial Approval (CTA) schemes, places the IB at the centre of a significantly less data-dense oversight environment. Where an IND in the US may run to hundreds of pages and include complete non-clinical study reports, detailed chemistry, manufacturing and controls (CMC) information, and comprehensive integrated safety summaries, the Australian IB is often the only document available to regulators for assessing the suitability of an investigational product for human exposure.

The ethical and legal implications of this choice are profound. This asymmetry creates a perverse incentive structure that has not been widely acknowledged in the clinical research community. Liability mitigation. In the event of an unexpected fatality, a serious adverse event, or significant participant harm occurring during an Australian trial, the sponsor’s defence against negligence claims would likely centre on the adequacy of the information provided to investigators and ethics committees. If the IB contained only minimal summaries, the minimum acceptable under Australian requirements, the sponsor would be vulnerable to allegations that investigators were not adequately warned of known or foreseeable risks, even if those risks were documented in the separate IND or IMPD that Australian regulators never saw.

This dynamic introduces double standards. The same drug developer that submits a 1,500-page IND to the FDA may submit a 90-page IB to an Australian HREC, even though the participants in the Australian trial face identical risks to those in the US trial. The only difference is the regulatory scrutiny applied to the safety documentation. Where the FDA demands full disclosure, the TGA and HRECs accept a summary. The sponsor who complies with the Australian minimum may be legally compliant but ethically questionable, and potentially civilly liable if harm occurs. The question arises as to whether sponsors should aim to develop two IBs: a typical IB and an Australian one, where, to avoid claims of negligent misstatement or failure to warn, the IB introduces the data density of an IND or IMPD into a document intended to be an 80–100 page summary.

Australian authorities currently seem content with the situation but there is no knowing how the public will respond to an Australian Tegenero or Bial incident.

New Demands on IB Authors and Sponsors

The practical implications for those responsible for IB preparation are substantial and vary by jurisdiction. Medical writers must master RSI construction principles, understand the regulatory definitions of expectedness, and develop processes for capturing and documenting the causality assessments that underpin RSI listings. Appendix A of E6 (R3) specifically notes that where an adverse reaction “is suspected to be medicinal product-related with a high level of certainty, it should be included in the reference safety information (RSI) and/or the Investigator’s Brochure (IB)” [8].

For sponsors operating in Australia, medical writers face an additional burden: determining whether an IB intended for Australian use should be expanded to incorporate some of the data that would normally reside in an IND or IMPD. The decision requires balancing regulatory efficiency against liability exposure, with no clear guidance from Australian authorities on what constitutes ‘sufficient’ information. The TGA’s guidance documents are notably limited on the depth of data required within an IB, instead referencing the ICH E6 structure without endorsing any particular level of detail [9].

Sponsors must also establish governance processes that treat the IB as a regulated, quality-managed asset rather than a static reference document. This requires integration between clinical development, safety/pharmacovigilance, regulatory affairs, and medical writing functions. Continuous updating demands version control systems that can accommodate multiple annual revisions, clear criteria for determining what constitutes ‘important’ new information as it emerges, requiring out-of-cycle communication, and robust processes for disseminating updated information to all investigators and ethics committees involved in ongoing trials, including those in Australia, where the TGA does not mandate centralised tracking of IB versions across sites (i.e, global studies).

A reasoned approach to mitigation focuses on contractual safeguards: obligations on the product developer to provide complete safety information equivalent to IND/IMPD standards, rights for the Australian sponsor to review and request IB amendments, contractual mechanisms for out-of-cycle safety communication, indemnities covering regulatory penalties where permitted, audit rights, and insurance requirements naming the Australian sponsor as an additional insured. These safeguards address the information asymmetry directly, rather than relying on the Australian sponsor to include information it cannot control.

Conclusion

Organisations must recognise E6 (R3) as a fundamental reset, not merely a routine guideline update, to be best positioned for the next decade of clinical research. The transition requires investment in training, process redesign, and cross-functional integration. But the alternative, treating E6 (R3) as business-as-usual with minor editorial adjustments, carries unacceptable risks to safety reporting integrity and regulatory compliance.

For sponsors conducting trials in Australia, an additional fork in the road demands immediate attention. Continuing to rely on the minimum information standard inherent in the CTN scheme, when fuller safety data exists in IND or IMPD documents, exposes participants to asymmetric risk and sponsors to asymmetric liability. The prudent but unspoken path is clear: Australian submissions should contain no less safety and technical information than would be provided to regulators in any major jurisdiction. Anything less is ethically indefensible and legally precarious.

The IB has evolved from a summary document into a regulated safety instrument. The question facing sponsors, medical writers, investigators, and regulators in 2026 is not whether to adapt, but how quickly, and how completely, to embrace the higher standards that participants deserve, regardless of which country’s regulatory framework governs their trial or which entity holds the sponsor role.

References

1. International Conference on Harmonisation. ICH Harmonised Guideline: Good Clinical Practice E6(R1). 1996.
2. Niche Science & Technology Ltd (2024). The Investigaor’s Brochure: An Insider’s Insight.
3. Rengelshausen J, Breithaupt-Grögler K, Donath F, et al. How to Interpret an Investigator’s Brochure for Meaningful Risk Assessment: Results of an AGAH Discussion Forum. Ther Innov Regul Sci. 2021;55:612-618.
4. EUFEMED Workshop. Making the Investigator's Brochure truly fit for purpose in early medicines development. Warsaw, 20 September 2024.
5. International Council for Harmonisation. ICH Harmonised Guideline: Good Clinical Practice E6(R3) Appendix A – Investigator’s Brochure. Step 5, 23 January 2025.
6. CATALIS Québec. Good Clinical Practices – ICH E6(R3): Updates to Support the Evolution of Clinical Research. 2026.
7. Emtex Life Science. Impact of the ICH E6(R3) Guideline on Clinical Trial Documents Frequently Prepared by Medical Writers. 2025.
8. Association of Clinical Research Professionals. ICH E6(R3): Delivering Quality Outcomes Through Compliance. 2026.
9. ICH GCP. Glossary: ICH E6(R3) Guideline on Good Clinical Practice. 2023.
10. Klepper MJ, Fontaine L. Survey of safety information in the investigator’s brochure: inconsistencies and recommendations. Ther Innov Regul Sci. 2018;52:764-770.
11. Therapeutic Goods Administration. Clinical trials: Investigator’s Brochure. Australian Government Department of Health